These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18841028)

  • 21. Is early virological response as predictive of the hepatitis C treatment response in dialysis patients as in non-uremic patients?
    Fucuta Pereira Pda S; Uehara SN; de Mello Perez R; Feldner AC; de Melo IC; de Souza e Silva IS; Silva AE; Ferraz ML
    Int J Infect Dis; 2013 Jan; 17(1):e50-3. PubMed ID: 23041364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.
    Tsukada H; Ochi H; Maekawa T; Abe H; Fujimoto Y; Tsuge M; Takahashi H; Kumada H; Kamatani N; Nakamura Y; Chayama K
    Gastroenterology; 2009 May; 136(5):1796-805.e6. PubMed ID: 19208361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load.
    Kawamura Y; Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kobayashi M; Kumada H
    Intern Med; 2008; 47(5):355-60. PubMed ID: 18310963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Japan-specific subtype of hepatitis C virus genotype 1b, J subtype, has relatively low pathogenicity.
    Nakano I; Fukuda Y; Katano Y; Toyoda H; Hayashi K; Kumada T; Nakano S
    J Med Virol; 2001 Sep; 65(1):45-51. PubMed ID: 11505442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection.
    Hsu CS; Liu CH; Liu CJ; Wang CC; Chen CL; Lai MY; Chen PJ; Chen DS; Kao JH
    Am J Gastroenterol; 2009 Mar; 104(3):598-604. PubMed ID: 19262519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients.
    Wada M; Marusawa H; Yamada R; Nasu A; Osaki Y; Kudo M; Nabeshima M; Fukuda Y; Chiba T; Matsuda F
    J Viral Hepat; 2009 Jun; 16(6):388-96. PubMed ID: 19200137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection.
    Hanouneh IA; Feldstein AE; Lopez R; Yerian L; Pillai A; Zein CO; Zein NN
    Clin Gastroenterol Hepatol; 2008 May; 6(5):584-9. PubMed ID: 18455698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C.
    Sanefuji K; Kayashima H; Iguchi T; Sugimachi K; Yamashita Y; Yoshizumi T; Soejima Y; Nishizaki T; Taketomi A; Maehara Y
    J Surg Oncol; 2009 Jan; 99(1):32-7. PubMed ID: 18985618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Method to detect substitutions in the interferon-sensitivity-determining region of hepatitis C virus 1b for prediction of response to interferon therapy.
    Nishiguchi S; Ueda T; Itoh T; Enomoto M; Tanaka M; Tatsumi N; Fukuda K; Tamori A; Habu D; Takeda T; Otani S; Shiomi S
    Hepatology; 2001 Jan; 33(1):241-7. PubMed ID: 11124842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study.
    Imazeki F; Yokosuka O; Fukai K; Saisho H
    Hepatology; 2003 Aug; 38(2):493-502. PubMed ID: 12883494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.
    Kobayashi S; Takeda T; Enomoto M; Tamori A; Kawada N; Habu D; Sakaguchi H; Kuroda T; Kioka K; Kim SR; Kanno T; Ueda T; Hirano M; Fujimoto S; Jomura H; Nishiguchi S; Seki S
    Liver Int; 2007 Mar; 27(2):186-91. PubMed ID: 17311612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.
    Gao DY; Zhang XX; Hou G; Jin GD; Deng Q; Kong XF; Zhang DH; Ling Y; Yu DM; Gong QM; Zhan Q; Yao BL; Lu ZM
    J Clin Microbiol; 2008 Nov; 46(11):3746-51. PubMed ID: 18832124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A liver slice culture-based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C.
    Chang ML; Sung KF; Sheen IS; Lin SM; Yeh CT
    J Viral Hepat; 2009 May; 16(5):359-66. PubMed ID: 19243501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan.
    Konishi I; Horiike N; Hiasa Y; Michitaka K; Onji M
    Intervirology; 2004; 47(2):114-20. PubMed ID: 15192276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification.
    Gordon SC; Dailey PJ; Silverman AL; Khan BA; Kodali VP; Wilber JC
    Hepatology; 1998 Dec; 28(6):1702-6. PubMed ID: 9828238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.
    Bruno S; Stroffolini T; Colombo M; Bollani S; Benvegnù L; Mazzella G; Ascione A; Santantonio T; Piccinino F; Andreone P; Mangia A; Gaeta GB; Persico M; Fagiuoli S; Almasio PL;
    Hepatology; 2007 Mar; 45(3):579-87. PubMed ID: 17326216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Necessities of interferon therapy in elderly patients with chronic hepatitis C.
    Ikeda K; Arase Y; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2009 May; 122(5):479-86. PubMed ID: 19375558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Two-step interferon rebound therapy for refractory chronic hepatitis C].
    Kato M; Yuki N; Kaneko A; Yamamoto K; Kasahara A; Masuzawa M; Hayashi N
    Nihon Rinsho; 2001 Jul; 59(7):1315-9. PubMed ID: 11494544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.